Novo Nordisk Resultados de beneficios anteriores

Pasado controles de criterios 6/6

Novo Nordisk ha aumentado sus beneficios a una tasa media anual de 14.9%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 1.7% anual. Los ingresos han ido creciendo a una tasa media de 14.1% al año. La rentabilidad financiera de Novo Nordisk es de 78.5%, y sus márgenes netos son de 36%.

Información clave

14.9%

Tasa de crecimiento de los beneficios

16.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	6.0%
Tasa de crecimiento de los ingresos	14.1%
Rentabilidad financiera	78.5%
Margen neto	36.0%
Próxima actualización de resultados	02 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Novo Nordisk. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

OTCPK:NONO.F Ingresos, gastos y beneficios (DKK Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	232,261	83,683	61,598	31,029
30 Sep 23	214,490	75,312	58,063	29,308
30 Jun 23	201,325	67,239	56,597	26,813
31 Mar 23	188,290	61,129	53,014	24,809
31 Dec 22	176,954	55,525	50,684	23,287
30 Sep 22	167,195	52,825	48,415	21,021
30 Jun 22	157,251	50,539	45,949	19,640
31 Mar 22	149,027	49,344	43,023	18,461
31 Dec 21	140,800	47,757	41,058	17,199
30 Sep 21	134,605	46,183	39,200	16,273
30 Jun 21	129,910	44,362	38,237	15,932
31 Mar 21	126,875	42,864	37,557	15,279
31 Dec 20	126,946	42,138	36,886	15,462
30 Sep 20	127,225	41,537	36,693	14,913
30 Jun 20	126,575	41,433	36,283	14,603
31 Mar 20	126,605	40,403	36,490	14,869
31 Dec 19	122,021	38,951	35,830	14,220
30 Sep 19	119,336	38,731	35,056	14,352
30 Jun 19	116,821	37,574	34,346	14,395
31 Mar 19	114,192	38,322	33,855	14,134
31 Dec 18	111,831	38,628	33,313	14,805
30 Sep 18	110,091	38,384	32,729	14,244
30 Jun 18	108,943	39,117	32,062	13,928
31 Mar 18	110,174	38,725	31,739	14,046
31 Dec 17	111,696	38,130	32,124	14,014
30 Sep 17	113,276	38,576	31,786	14,501
30 Jun 17	114,199	38,609	32,268	14,631
31 Mar 17	113,020	38,626	32,390	14,548
31 Dec 16	111,780	37,925	32,339	14,563
30 Sep 16	111,084	37,484	32,467	13,884
30 Jun 16	110,339	36,064	32,495	13,715
31 Mar 16	109,939	34,439	32,817	13,419
31 Dec 15	107,927	34,860	32,169	13,608
30 Sep 15	103,636	33,131	30,712	13,616
30 Jun 15	99,093	31,248	29,578	13,381
31 Mar 15	93,663	29,899	27,870	13,421
31 Dec 14	88,806	26,481	26,760	13,762
30 Sep 14	85,919	26,005	26,571	12,863
30 Jun 14	84,181	25,920	26,153	12,604
31 Mar 14	83,932	25,660	26,448	12,244
31 Dec 13	83,572	25,184	26,888	11,733
30 Sep 13	82,836	24,886	26,514	11,377
30 Jun 13	82,170	24,138	26,228	11,199

Ingresos de calidad: NONO.F tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (36%) de NONO.F son superiores a los del año pasado (31.4%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de NONO.F han crecido un 14.9% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de NONO.F en el último año (50.7%) supera su media de 5 años (14.9% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de NONO.F en el último año (50.7%) superó al de la industria Pharmaceuticals -6.8%.

Rentabilidad financiera

Alta ROE: La rentabilidad financiera (78.5%) de NONO.F se considera excepcional.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Novo Nordisk Resultados de beneficios anteriores

Pasado controles de criterios 6/6

Información clave

Actualizaciones de resultados anteriores recientes

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Novo Nordisk A/S to Report Fiscal Year 2023 Results on Jan 31, 2024

Novo Nordisk A/S to Report First Half, 2023 Results on Aug 10, 2023

Novo Nordisk A/S to Report Fiscal Year 2022 Results on Feb 01, 2023

Recent updates

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.

Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis

Novo Nordisk A/S (CPSE:NOVO B) acquired Embark Biotech ApS for approximately €470 million.

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion.

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) for €99.1 million.

Novo Nordisk Enters into Exclusive Negotiations to Acquire A Controlling Stake in Bicorp, to Be Followed by A Tender Offer on All Remaining Shares

Novo Nordisk A/S Announces Headline Results from OASIS 1

Novo Nordisk A/S to Report Fiscal Year 2023 Results on Jan 31, 2024

Heartseed and Novo Nordisk A/S Announces First Patient Dosed in Clinical Study with HS-001 – A Cell Therapy Designed to Restore Heart Function in People with Advanced Heart Failure

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 28,000 million worth of its shares.

Novo Nordisk Announces FDA Approval of Label Update for Rybelsus® (Semaglutide) Allowing Use as a First-Line Option for Adults with Type 2 Diabetes

Novo Nordisk A/S to Report First Half, 2023 Results on Aug 10, 2023

Novo Nordisk Announces Headline Results from the ONWARDS 5 Phase 3A Trial with Once-Weekly Insulin Icodec in People with Type 2 Diabetes

Novo Nordisk A/S (CPSE:NOVO B) entered into a definitive agreement to acquire Forma Therapeutics Holdings, Inc. (NasdaqGM:FMTX) from RA Capital Management, L.P. and others for approximately $990 million

Novo Nordisk A/S (CPSE:NOVO B) entered into a definitive agreement to acquire Forma Therapeutics Holdings, Inc. (NasdaqGM:FMTX) from RA Capital Management, L.P. and others for approximately $990 million

Novo Nordisk A/S Successfully Completes Phase 2 Trial with Cagrisema in People with Type 2 Diabetes

Novo Nordisk A/S Revises Earnings Guidance for the Full Year of 2022

Novo Nordisk Achieves Primary Objectives of Onwards 3 and 4 Trials with Once-Weekly Insulin Icodec Demonstrating Superior Reduction in Hba1c Vs Insulin Degludec in Onwards 3

Novo Nordisk Achieves Primary Objectives of ONWARDS 1 and 6 Trials

Novo Nordisk A/S to Report Fiscal Year 2022 Results on Feb 01, 2023

Novo Nordisk Announces US Food and Drug Administration Approve A 2.0 Mg Dose of Ozempic®

Novo Nordisk A/S Announces Board Changes

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 22,000 million worth of its shares.

Novo Nordisk A/S Provides Earnings Guidance for the Year 2022

Novo Nordisk A/S Announces Settlement of Securities Lawsuit in Denmark

Novo Nordisk Announces Health Canada Approves Wegovy™ for the Treatment of Adults with Obesity

Novo Nordisk Presents Investigational 2 Mg Dose of Ozempic® (Semaglutide) Injection Demonstrates Superior Reductions in Blood Sugar Vs Ozempic® 1 Mg in Adults with Type 2 Diabetes in A Phase 3 Trial

US Food and Drug Administration Approves Wegovy of Novo Nordisk

Novo Nordisk Resubmits Once-Weekly Semaglutide 2.0 Mg for the Treatment of Type 2 Diabetes for US Regulatory Approval

Novo Nordisk Presents Results from RESCUE

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Desglose de ingresos y gastos
Beta